secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K/A
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001558370-24-016346
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pharmagesic financials: $4.9M loss, $82M deficit; Dogwood provides $19.5M funding
--------------------------------------------------------------------------------

- Pharmagesic (Holdings) Inc. (acquired Oct 7) had $4.9M net loss in 2023; no revenue; R&D costs $3.9M.
- As of Dec 2023, stockholders' deficit was $78.7M, accumulated deficit $82.0M; total liabilities $65.1M.
- Post-Dec 2023, $63.4M due to fellow subsidiaries settled; $36.0M preferred shares exchanged for common.
- Dogwood secured $19.5M loan from CK Life Sciences to fund Pharmagesic operations through early 2026.
- Halneuron (tetrodotoxin) is the lead candidate for chemotherapy-induced neuropathic pain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024016346/0001558370-24-016346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837024016346/dwtx-20241004x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer